CXCR4 antogonists

Several CCR5 antagonists, which inhibit the entry of HIV-1 in the host cell, have proven a valuable strategy for the treatment of AIDS. However, the virus can switch to the CXCR4 co-receptor to enter cells, thus prompting the need for CXCR4 antagonists.
In a review published in the January issue of Expert Opinion on Therapeutic Patents, Dr Liotta explores the preclinical development of such compounds, and finds that this relatively recent field could offer therapeutic options in several disease areas.